GlobalData on MSN12h
PTC Therapeutics ALS drug fails to meet endpoints as trials shut down
New Jersey-based biopharma, PTC Therapeutics said its Phase II trial of utreloxastat for patients with amyotrophic lateral ...
PTC Therapeutics to End Development of ALS Treatment
PTC Therapeutics will scrap development of its treatment for amyotrophic lateral sclerosis after it failed to meet a primary endpoint in a Phase 2 trial.
An artist with ALS creates beautiful portraits of people with the fatal disease
ALS is a progressive neurodegenerative disease — and there is no cure. Brunner, who was running 3 miles a day at the onset of ...
ALS News Today1d
Lilly to develop ALS therapies against targets ID’d with Verge tech
The Converge platform validated as many as 83% of its treatment targets in disease models, a higher success rate than usual ...
GlobalData on MSN1d
MaaT Pharma eyes Phase II after early success in ALS microbiome trial
The company’s oral, microbiome-changing therapy was well tolerated in patients with amyotrophic lateral sclerosis.